# Study of URC102 to Assess the Safety and Efficacy in Gout Patients

> **NCT02557126** · PHASE2 · COMPLETED · sponsor: **JW Pharmaceutical** · enrollment: 76 (actual)

## Conditions studied

- Gout
- Hyperuricemia

## Interventions

- **DRUG:** URC102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02557126
- **Lead sponsor:** JW Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2017-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02557126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02557126, "Study of URC102 to Assess the Safety and Efficacy in Gout Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02557126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*